Compare

How ACE-031 and Follistatin compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How ACE-031 and GDF-11 compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Acetyl Tetrapeptide-3 and GHK-Cu compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Acetyl Tetrapeptide-5 and Argireline compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Adipotide and Semaglutide compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Adipotide and Tesofensine compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How AICAR and MOTS-c compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Amycretin and CagriSema compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Amycretin and Semaglutide compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Anamorelin and MK-677 compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

AOD-9604 vs HGH Fragment 176-191: the structural difference, stability, human evidence, fat-loss claims, risks, and honest by-goal picks.

How AOD-9604 and IGF-1 LR3 compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

AOD-9604 vs Semaglutide: AOD-9604 failed its obesity program while Semaglutide produced about 15% mean weight loss in STEP 1.

How AOD-9604 and Sermorelin compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

AOD-9604 vs Tesamorelin tests a GH fragment against a GHRH analog: one missed in obesity, while one reduced visceral fat in HIV trials.

ARA-290 vs BPC-157: human neuropathy trials versus animal soft-tissue research, with honest evidence grades and practical by-goal picks.

How ARA-290 and Humanin compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

ARA-290 vs LL-37 compares a repair signal with a membrane-disrupting host-defense peptide, including evidence, safety, and goal-specific picks.

ARA-290 vs Thymosin Alpha-1 compares two immune peptides with human trials: neuropathy-focused cibinetide versus broader immune drug thymalfasin.

Argireline vs GHK-Cu: choose Argireline for expression lines or GHK-Cu for repair, firmness and tone, with an honest look at the evidence.

Argireline vs Matrixyl compared by mechanism, wrinkle type, evidence, safety and use: see which topical peptide fits each skincare goal.

Argireline vs Palmitoyl Tripeptide-1 compared by wrinkle type, mechanism and evidence, with honest picks for dynamic lines and static lines.

How Argireline and Pentapeptide-18 compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

Argireline vs SNAP-8 compares two topical expression-line peptides: Argireline has human trials, while SNAP-8's stronger claim lacks direct proof.

Argireline vs Syn-Ake compares two topical expression-line peptides by mechanism, wrinkle goal, human evidence, safety, and US cosmetic status.

How B7-33 and BPC-157 compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How B7-33 and TB-500 compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Bimagrumab and Follistatin compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Bimagrumab and Semaglutide compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Biotinoyl Tripeptide-1 and GHK-Cu compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How BPC-157 and Cartalax compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

BPC-157 vs CJC-1295 for recovery: compare animal-only tissue-repair evidence with human GH/IGF-1 data, risks, andundefinedFDA status.

BPC-157 vs GHK-Cu: one is studied for deep-tissue and gut repair, the other is a copper peptide for skin — how their evidence, uses and legal status compare.

BPC-157 vs IGF-1 LR3: both are animal-only for injury repair, but BPC-157 has closer tendon evidence while IGF-1 LR3 carries broader growth risks.

BPC-157 vs Ipamorelin compares animal-only tissue-repair evidence with a GH-release mechanism, plus honest by-goal picks andundefinedFDA status.

BPC-157 vs KPV compares broad tissue and gut repair with targeted anti-inflammatory research for gut and skin, with honest by-goal picks.

BPC-157 vs Larazotide flips the popularity story: animal-only gut-healing research versus human celiac RCTs that did not reach approval.

BPC-157 vs MK-677 compares animal-only tissue-repair evidence with human GH trials, real metabolic costs, andundefinedUS legal status.

BPC-157 vs Pentadeca Arginate: compare structure, claimed stability, evidence, reported use, safety, andundefinedUS research-only status.

BPC-157 leans local (tendons, gut), TB-500 leans systemic, both are animal-strong and human-thin, and plenty of people run both. Here's which fits which goal.

How BPC-157 and Teduglutide compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How BPC-157 and Teriparatide compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How BPC-157 and Thymosin Beta-4 compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Cagrilintide and Petrelintide compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Cagrilintide and Pramlintide compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

Cagrilintide vs Retatrutide compared by receptors, human weight-loss trials, safety, regulatory status, and the untested stack question.

Cagrilintide vs Semaglutide compares an investigational amylin analogue with an approved GLP-1 drug, including weight loss, dosing, and CagriSema.

Cagrilintide vs Tirzepatide compares amylin-only research with an approved dual GIP/GLP-1 drug, without treating separate trials as a fair race.

CagriSema vs Orforglipron: compare a pending weekly injection with 2026-approved Foundayo on weight loss, dosing, convenience, and evidence.

CagriSema vs Retatrutide compared by mechanism, human trial weight loss, evidence maturity, studied doses, side effects, andundefinedFDA status.

CagriSema vs Semaglutide: REDEFINESemaglutidefound more weight loss with the combo, while Semaglutide retains approval and longer outcomes data.

CagriSema vs Tirzepatide: compare mechanisms, Phaseundefinedweight-loss results, safety, approval status, and the better fit for different goals.

How Cartalax and Pentadeca Arginate compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Cerebrolysin and Cortexin compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

Cerebrolysin vs Dihexa: human stroke and TBI trials versus animal-only synaptogenesis data, retractions, regulation, and by-goal picks.

Cerebrolysin vs Noopept compares an injectable porcine peptide mixture with an oral small molecule, including evidence, doses, risks, and best-fit goals.

Cerebrolysin vs P021 compares a porcine-brain hydrolysate with a CNTF-derived research peptide. See the origin myth, evidence gap, and by-goal picks.

Cerebrolysin vs Selank: injected neurorecovery drug versus intranasal anxiety peptide, with honest evidence tiers and no universal winner.

Cerebrolysin vs Semax compares an injectable porcine peptide mixture with a short intranasal peptide by evidence, route, goals, and risks.

CJC-1295 vs GHRP-2 compares two GH levers usually paired, not substituted: human evidence, side effects, synergy, andundefinedcompounding status.

CJC-1295 vs GHRP-6 compares sustained GHRH signaling with a short, hunger-heavy ghrelin pulse, using human GH data and currentundefinedstatus.

CJC-1295 vs IGF-1 LR3 compares an upstream GH releaser with a direct IGF-1 signal, including evidence, half-life claims, and risks.

CJC-1295 raises your growth-hormone baseline, ipamorelin fires the pulse, and most people run both. What each does, the evidence, and how they stack.

CJC-1295 vs MK-677 compares an injectable GHRH analog with oral ibutamoren, including human evidence, glucose risk, andundefinedFDA status.

CJC-1295 vs Modified GRF 1-29 comes down to DAC, half-life, GH pattern, dosing frequency, and how much direct human evidence supports each form.

CJC-1295 vs Sermorelin compared by duration, human evidence, dosing frequency, safety and US status, with honest picks for different goals.

CJC-1295 vs Tesamorelin compares a long-acting research GHRH analog with an FDA-approved daily treatment for HIV-associated visceral fat.

See dulaglutide vs tirzepatide compared by mechanism, A1c, weight, devices, approvals, side effects, and the goal each weekly drug fits best.

Survodutide vs Tirzepatide compares GLP-1/glucagon with GLP-1/GIP, separate weight-loss trials, doses, risks, and US status in 2026.

How Cortagen and Epitalon compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Danuglipron and Orforglipron compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Danuglipron and Semaglutide compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Davunetide and Semax compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Decapeptide-12 and Melitane compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

Defensins vs LL-37 compares a peptide family with one 37-residue cathelicidin, including structure, evidence, dosing, andundefinedstatus.

Dihexa vs Noopept compares animal-only synaptogenesis research with limited human cognitive data, including mechanisms, doses, risks and legal status.

Dihexa vs p21 compares two animal-only nootropics: Dihexa for synaptogenesis models and P021 for neurogenesis, with Dihexa's retractions explained.

Dihexa vs Selank compared by goal, mechanism, human evidence, safety, and the 2025 Dihexa retraction—without pretending there is one winner.

Dihexa vs Semax compares animal-only HGF/c-Met research with Semax's Russian human experience, intranasal use, risks, and by-goal picks.

Dulaglutide vs Exenatide: what AWARD-1 found on HbA1c, weight and hypoglycemia, plus theundefinedreality for Trulicity, Byetta and Bydureon.

Dulaglutide vs liraglutide compares weekly Trulicity with daily Victoza or Saxenda across A1c, weight, dosing, devices, risks and FDA uses.

Dulaglutide vs Semaglutide: SUSTAIN 7, A1c, weight, pen design, oral options, safety, and by-goal picks for Trulicity and Ozempic.

How Ecnoglutide and Semaglutide compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Epidermal growth factor (EGF) and GHK-Cu compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

Epitalon vs FOXO4-DRI compares telomerase-linked and senolytic theories, animal-only evidence, safety gaps, and by-goal research picks.

Epitalon vs GHK-Cu compares telomere research with copper-peptide skin data, including evidence tiers, routes, risks, and by-goal picks.

Epitalon vs Humanin compared by origin, mechanism, evidence, safety and goal—without treating animal results as proof of human longevity.

How Epitalon and Livagen compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

Epitalon vs MOTS-c compares telomere and circadian research with mitochondrial metabolism, using honest evidence tiers and no universal winner.

Epitalon vs NAD+ compares telomere and pineal research with coenzyme support for energy metabolism, DNA repair, evidence, safety, and delivery.

How Epitalon and Pinealon compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

Epitalon vs SS-31 (elamipretide) compares telomere and circadian research with mitochondrial cardiolipin targeting, including the evidence and FDA-status gap.

Epitalon vs Thymalin compared: a defined pineal tetrapeptide versus a thymus extract, with honest evidence tiers and by-goal picks.

How Epitalon and Vesugen compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

Exenatide vs Liraglutide, using LEAD-6 and DURATION-6 to compare blood sugar, weight, nausea, dosing, and US availability in 2026.

A practical exenatide vs semaglutide comparison of dosing, devices, trial results, FDA uses, side effects, and the better fit for different goals.

Follistatin vs GDF-11 compares a pathway inhibitor with an aging-linked ligand. See the muscle evidence, disputed mouse data, risks, and goal-based picks.

Follistatin vs IGF-1 LR3: two animal-only muscle-growth mechanisms compared by evidence, systemic risks, legal status, and research goal.

How Follistatin and Klotho compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

Follistatin vs MK-677 compares myostatin brake removal with oral GH/IGF-1 stimulation, including evidence, delivery, risks, and by-goal picks.

FOXO4-DRI vs nad+ compares senescent-cell clearance with NAD+ repletion, separating animal evidence, human trials, safety, andundefinedstatus.

GHK-Cu vs KPV compares skin and matrix repair with inflammation control, using honest evidence tiers to explain whether both belong in KLOW.

GHK-Cu vs Matrixyl compares two topical collagen peptides by mechanism, evidence, skin goal, safety, and formulation fit—without naming one winner.

GHK-Cu vs Palmitoyl Tripeptide-1: copper delivery versus a lipid-tailed collagen signal, with honest evidence tiers and by-goal picks.

GHK-Cu vs pentadeca arginate: human skin research for GHK-Cu meets a PDA record with no published efficacy studies or direct trial.

GHK-Cu vs SNAP-8 compares a copper peptide for structural skin remodeling with a topical expression-line peptide—and grades the evidence behind each.

GHK-Cu vs Syn-Ake compares a copper signal peptide with a snake-venom mimic: different wrinkle targets, evidence tiers, and regulatory limits.

GHK-Cu vs TB-500: GHK-Cu has human cosmetic skin data; TB-500 has no human healing evidence. Compare mechanisms, uses, andundefinedFDA status.

GHRP-2 vs GHRP-6: compare appetite, GH release, side effects, evidence and legal status, with a different pick for each practical goal.

GHRP-2 vs Hexarelin: direct human data finds similar acute GH and cortisol/prolactin responses, while both lose response with repeated dosing.

GHRP-2 vs Ipamorelin compares GH-pulse strength, selectivity, appetite, hormone spillover, evidence, and the better fit for each goal.

GHRP-2 vs MK-677 compares a short injected GH pulse with a longer oral IGF-1 signal, including evidence, risks, and by-goal picks.

GHRP-2 vs Modified GRF 1-29 compares complementary GH pathways, unequal human evidence, hormone spillover, stack roles, andundefinedstatus.

GHRP-6 vs Hexarelin: GHRP-6 drives stronger hunger, while Hexarelin produces a harder short-term GH pulse that fades with repeated dosing.

GHRP-6 vs Ipamorelin compares hunger, GH release, hormone selectivity, side effects and reported use patterns without declaring one universal winner.

GHRP-6 vs MK-677 compares a short injectable hunger spike with daily oral ghrelin signaling, including glucose, heart-failure and evidence trade-offs.

How Gonadorelin and Kisspeptin-10 compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Hexapeptide-11 and Matrixyl compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

Hexarelin vs Ipamorelin: compare GH potency, desensitization, side effects, use patterns, and which peptide better fits each research goal.

Hexarelin vs MK-677 compares an injectable GH peak with an oral IGF-1 lift—and the different durability and safety costs each carries.

How HGH Fragment 176-191 and Tesamorelin compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

Humanin vs MOTS-c compares two mitochondrial peptides: Humanin for cell protection and MOTS-c for metabolic and exercise research, with evidence graded.

Humanin vs nad+ compares a mitochondrial-derived peptide with a cellular coenzyme, including evidence tiers, legal status and by-goal picks.

Humanin vs SS-31 compares cytoprotective signaling with cardiolipin-targeted ATP support, including human evidence, safety, and picks by research goal.

How IGF-1 DES and IGF-1 LR3 compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

IGF-1 LR3 vs Ipamorelin: neither has human muscle-growth evidence, but LR3 bypasses pituitary feedback and brings a different risk profile.

How IGF-1 LR3 and MGF peptide compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

IGF-1 LR3 vs MK-677 compares direct IGF-1 signaling with an oral GH secretagogue, including evidence, route, goal-based picks, and risks.

How IGF-1 LR3 and Trofinetide compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Ipamorelin and Macimorelin compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

Ipamorelin vs mod grf 1-29 compares two complementary GH-release signals, their thin human evidence, risks, and 2026 compounding status.

Ipamorelin vs sermorelin: a ghrelin-mimetic GHRP versus a GHRH analog — two different ways to raise your own growth hormone, and why people combine them.

Ipamorelin vs Tesamorelin: Tesamorelin has human visceral-fat RCTs; Ipamorelin has no human body-composition efficacy trial.

How Kisspeptin-10 and PT-141 compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

KPV vs Larazotide compares an animal-only anti-inflammatory tripeptide with a human-tested tight-junction peptide whose Phaseundefinedtrial failed.

KPV vs LL-37 compared by mechanism, gut and skin research, safety, and evidence—plus why antimicrobial and anti-inflammatory are not interchangeable.

KPV vs pentadeca arginate: KPV has mouse gut-inflammation data; PDA has no published human or peer-reviewed animal efficacy study we could find.

KPV vs TB-500 compares an anti-inflammatory alpha-MSH fragment with a tissue-repair peptide, including evidence tiers andundefinedFDA review.

KPV vs thymosin alpha-1 compares an animal-only anti-inflammatory peptide with a human-tested immune modulator, including the 2026 FDA picture.

How Lactoferrin and LL-37 compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Larazotide and Teduglutide compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

A liraglutide vs semaglutide comparison of dosing, brands, weight-loss trials, side effects and goals, without pretending one drug wins for everyone.

Liraglutide vs Tirzepatide compares daily GLP-1 treatment with a weekly dual agonist, including trial weight loss, brands, doses, and by-goal picks.

LL-37 vs Thymosin Alpha-1 compares direct innate antimicrobial action with T-cell immune tuning, including evidence, risks, andundefinedUS status.

How Macimorelin and MK-677 compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How MariTide and Retatrutide compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How MariTide and Tirzepatide compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

Matrixyl vs Palmitoyl Tripeptide-1 explained: original Pal-KTTKS compared with Pal-GHK, a component of Matrixyl 3000, by formula and evidence.

How Matrixyl and Palmitoyl Tripeptide-38 compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

Matrixyl vs SNAP-8 compares collagen signaling, expression lines, evidence and topical use, with honest by-goal picks and no overall winner.

Matrixyl vs Syn-Ake compared by mechanism, wrinkle type, evidence and timing—plus why Matrixylundefinedis not the same ingredient.

Mazdutide vs Retatrutide compares dual versus triple agonism, human weight-loss evidence, trial doses, safety, andundefinedUS regulatory status.

Mazdutide vs Semaglutide compares dual GLP-1/glucagon action with approved GLP-1 therapy across weight loss, evidence, safety, andundefinedstatus.

Mazdutide vs Survodutide compares two GLP-1/glucagon dual agonists by trials, safety, regulation, and goal without forcing one winner.

Mazdutide vs Tirzepatide compares GLP-1/glucagon with GIP/GLP-1, separate weight-loss trials, safety, and US status in 2026.

Melanotanundefinedvsundefinedcompares receptor selectivity, tanning, libido effects, mole monitoring, evidence, dosing, and US approval status in 2026.

Melanotan 1 vs Melitane compares an FDA-approved 16 mg implant with an accessible topical MC1R agonist, including evidence, access, and by-goal picks.

Melanotanundefinedvs PT-141 compares an MC1R-focused EPP implant with an MC4R-linked HSDD drug, including approvals, evidence, doses, and risks.

Melanotanundefinedvs Setmelanotide: MC1R pigment drug versus MC4R obesity drug, with approved uses, evidence tiers, formats, and risks.

Melanotanundefinedvs PT-141 compares broad tanning and libido effects with an FDA-approved, libido-focused drug. See the evidence, risks, and by-goal picks.

Melanotanundefinedvs Setmelanotide comes down to receptor selectivity, evidence and legal status: broad unapproved MT-II versus prescribed IMCIVREE.

Melanotan II vs Melitane compares an unapproved tanning injection with a topical cosmetic peptide whose human tanning evidence remains unproven.

How Melanotan II and Nonapeptide-1 compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Melitane and Nonapeptide-1 compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

MK-677 vs Ipamorelin compares an oral, long-acting ghrelin mimetic with a short-acting injectable peptide, including evidence, risks, and by-goal picks.

MK-677 vs Semaglutide compares a hunger-driving GH secretagogue with an FDA-approved GLP-1 appetite suppressant, including the lean-mass trade-off.

MK-677 vs Sermorelin compares an oral ghrelin mimetic with an injectable GHRH analog across evidence, side effects, route and legal status.

How MK-677 and Somatropin compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

MK-677 vs Tesamorelin compares an oral ghrelin mimetic with an FDA-approved injectable GHRH analog, including evidence, visceral fat, risks, and route.

Modified GRF 1-29 vs Sermorelin explained: four sequence changes, different human evidence, FDA history, 503A status, and the CJC no-DAC naming trap.

Modified GRF 1-29 vs Tesamorelin: same GHRH idea, sharply different proof. Compare structure, human data, FDA status, dosing, and by-goal picks.

MOTS-c vs NAD+ compares a mitochondrial-derived peptide with coenzyme repletion across mechanism, human evidence, delivery, safety, and research goals.

How MOTS-c and Retatrutide compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

MOTS-c vs Semaglutide is mouse metabolic research versus an FDA-approved GLP-1 with human weight-loss trials. Compare evidence, risks, and goals.

How MOTS-c and SLU-PP-332 compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

MOTS-c vs SS-31 (elamipretide) compares metabolic signaling with cardiolipin targeting, human evidence, delivery, safety, and the better fit by research goal.

How MOTS-c and Thymalin compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How N-Acetyl Semax Amidate and Semax compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

Nad+ vs SS-31 (elamipretide): compare a metabolic coenzyme with a cardiolipin-targeting peptide, including human evidence and Forzinity's narrow FDA approval.

Noopept vs P021 compares controlled human exposure with rodent-only neurogenesis research, including BDNF claims, studied doses, risks, and US status.

Noopept vs selank compared for focus, memory, anxiety, route, evidence and safety—with honest by-goal picks and no universal winner.

This orforglipron vs retatrutide comparison weighs an approved daily pill against an investigational weekly triple agonist, without crowning one winner.

Orforglipron vs Semaglutide compares a flexible daily pill with established oral and weekly-shot options, including trial results, risks, and access.

Orforglipron vs Tirzepatide compares a daily oral GLP-1 pill with a weekly dual GIP/GLP-1 shot, including trials, risks, and by-goal picks.

How Oxytocin and Selank compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

P021 vs Selank compares an animal-only CNTF-derived neurogenesis compound with a tuftsin analog backed by a small Russian anxiety trial.

P21 vs Semax compares two animal-only nootropic claims: CNTF-derived P021 for neurogenesis and intranasal Semax for stroke and cognition research.

Palmitoyl Tripeptide-1 vs SNAP-8: compare a collagen signal peptide with a wrinkle-focused neuropeptide, including evidence limits and by-goal picks.

How Pancragen and Semaglutide compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How PE-22-28 and Semax compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Pemvidutide and Retatrutide compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Pemvidutide and Survodutide compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

Pentadeca Arginate vs TB-500 compares PDA's untested stability pitch with TB-500's animal evidence, mechanisms, reported use, and risks.

How Petrelintide and Semaglutide compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

PT-141 vs setmelanotide compares two FDA-approved melanocortin drugs: one for low sexual desire, the other for genetic or hypothalamic obesity.

A retatrutide vs survodutide comparison of receptors, phase 3 weight loss, liver evidence, research doses, risks, and 2026 approval status.

Retatrutide vs tirzepatide: the investigational triple agonist versus the FDA-approved dual agonist — mechanism, trial weight loss and legal status compared.

How Retatrutide and VK2735 compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

Semaglutide vs Setmelanotide is not a potency contest: compare diagnoses, mechanisms, human evidence, dosing, and currentundefinedFDA indications.

Semaglutide vs Survodutide compares an approved GLP-1 drug with an investigational GLP-1/glucagon dual agonist for weight and liver goals.

Semaglutide vs Tesamorelin: broad weight loss versus targeted visceral-fat reduction, with human evidence, FDA limits, and by-goal picks.

Semaglutide vs tirzepatide: tirzepatide led on weight in the SURMOUNT-5 head-to-head, but semaglutide has an oral option and the longer track record.

Semax vs Noopept compares an intranasal peptide with an oral nootropic, including evidence, onset, study doses, risks, and by-goal picks.

Semax vs Selank compares two Russian intranasal peptides: Selank for anxiety and calm, Semax for focus and cognition, with honest evidence grades.

How Sermorelin and Somatropin compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

Sermorelin vs Tesamorelin: compare approval history, visceral-fat evidence, GH release, study doses, risks, and the better fit by goal.

SNAP-8 vs Syn-Ake compares two topical expression-line peptides by mechanism, evidence, potency claims, safety, and the skincare goal each best fits.

How SS-20 and SS-31 (elamipretide) compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How TB-500 and Teriparatide compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

TB-500 vs Thymosin Beta-4: the fragment and full peptide compared by structure, evidence, reported use, and US research-only status.

Tesofensine vs Semaglutide compares separate human trials, mechanisms, heart-rate risks, and their very different FDA status in 2026.

How Tesofensine and Tirzepatide compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

This retatrutide vs semaglutide comparison covers mechanism, trial weight loss, 2026 approval status, evidence, dosing, and format.

How Thymalin and Thymogen compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

Thymalin vs Thymosin Alpha-1 compares a thymic peptide mixture with a defined 28-amino-acid drug, including evidence, dosing, and US status.

How Thymalin and Thymosin Beta-4 compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

Thymalin vs Thymulin compares a thymic peptide preparation with a zinc-dependent nonapeptide, including evidence, research focus, and US status.

How Thymalin and Vilon compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Thymopentin and Thymosin Alpha-1 compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

Thymosin Alpha-1 vs Thymosin Beta-4: immune evidence, repair claims, human trials, FDA status, and honest by-goal picks without one winner.

Thymosin Alpha-1 vs Thymulin: a no-hype comparison of molecule, mechanism, human evidence, research dosing, and unsettled US compounding status.

How Thymosin Beta-4 and Thymulin compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.

How Tirzepatide and VK2735 compare on evidence, dosing, risks, and 2026 US legal status — with an honest, by-goal verdict.